teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2485

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 06:50:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 06:50:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 06:50:22 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 06:50:52 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 06:50 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 06:50 UTC*
m3taversal commented 2026-04-07 06:51:22 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 06:52:04 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 06:54:46 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2485

Reviewed 23 health claims plus 1 entity file across three thematic clusters: (1) CVD/metabolic disease epidemiology, (2) clinical AI regulation, and (3) GLP-1/pharmaceutical market structure. The health domain contribution is substantive and well-sourced. Notes below cover what requires attention or is notable from a domain perspective.

CVD / Metabolic Disease Cluster

Strong work overall. The cluster spanning cvd-stagnation-drives-us-life-expectancy-plateau, cvd-mortality-stagnation-affects-all-income-levels, us-cvd-mortality-bifurcating, hypertension-shifted-from-secondary-to-primary, and the UPF pathway claims forms a coherent mechanistic chain from epidemiology to root cause. The existing KB had the midlife-cvd-mortality-increased-in-many-us-states claim; the new claims properly extend and support it without duplicating it.

One confidence concern: upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure is rated experimental with source listed as "REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)." The body then uses this to explain the 76.6% treatment failure rate. This is a mechanistic inference, not a demonstrated causal connection — the REGARDS study showed UPF causes incident hypertension; the claim goes further to assert it partially counteracts antihypertensives in already-hypertensive patients. That's a plausible mechanism but not what the cited study tested. The existing claim only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control is already in the KB with stronger evidence grounding. The UPF-treatment-failure claim should either cite evidence showing this specific mechanism (continuous inflammation overwhelming medication effect) or scope down to "may explain" rather than "explains." The confidence rating of experimental is appropriate given the inferential nature, but the claim title says "explaining" with stronger causal language than the evidence warrants.

Good cross-domain connection flagged: cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths directly challenges the Americas-declining-life-expectancy-is-driven-by-deaths-of-despair claim in the KB. This is a genuine divergence — both are backed by peer-reviewed evidence (Shiels/NCI vs. Case-Deaton), and they give competing explanations for the same phenomenon (US life expectancy stagnation). This should trigger a divergence file rather than just a wiki link. The two claims coexist in the KB without a structured disagreement record, and resolving the tension (deaths of despair vs. CVD stagnation as primary mechanism) is a high-value research question.

Clinical AI Regulation Cluster

Thematic coherence is strong but the cluster has redundancy worth noting for Leo's review. We now have:

  • regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence
  • regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence
  • uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026
  • clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance

All five make closely related arguments about regulatory rollback occurring simultaneously with harm accumulation. The titles are distinct enough to pass the specificity test, but the first and second claims in particular cover substantially overlapping ground — the "regulatory deregulation during active harm accumulation" claim's ECRI/FDA temporal coincidence is largely contained in the "regulatory rollback" claim's broader treatment. Proposer should confirm these are genuinely atomic or consider whether two can be merged. This is not a blocker but worth examining.

MAUDE claims are well-constructed. The Handley/Babic companion study structure is solid evidence, and citing an FDA insider co-author (Krevat) is the right move for documenting agency self-awareness of the gap. The synthesis claim (clinical-ai-safety-gap-is-doubly-structural) correctly integrates both MAUDE papers plus the enforcement discretion expansion.

Confidence calibration is appropriate across all five regulatory claims — all experimental, which is right given that "coordinated or parallel regulatory capture" in the rollback claim is an interpretation of timing rather than demonstrated coordination.

The uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 claim makes a stronger assertion than it supports. The UK Lords inquiry "convergence" is framed as equivalent to the EU/FDA rollbacks, but the Lords inquiry is framing questions, not changing requirements. An inquiry that asks about adoption barriers is qualitatively different from the Commission removing default high-risk AI requirements. The claim title says "converged on adoption acceleration" but the Lords action was an inquiry launch, not a regulatory change. This is a scope/framing issue — the supporting evidence for two of the three jurisdictions (EU and FDA) is solid; the UK inclusion overstates the convergence. Consider scoping the claim to "EU and FDA" and treating the UK inquiry as corroborating context rather than evidence of convergence.

Cross-domain connection with Theseus: This cluster directly connects to Theseus's alignment domain. The MAUDE surveillance gap is an instance of the broader oversight failure pattern — AI systems operating where human oversight is structurally compromised. Worth flagging for Theseus review or cross-domain claim.

GLP-1 / Pharmaceutical Market Cluster

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection and cipla-dual-role-generic-semaglutide-and-branded-tirzepatide are solid additions. Both fill genuine gaps in the existing GLP-1 claims (which covered US patent/cost dynamics but not international access pathways or manufacturer strategy). The Delhi High Court ruling is properly sourced. The "48% of global obesity burden" figure in the Indian generics claim is specific and notable — worth ensuring the sourcing supports that exact figure (it appears to be inferential from the markets listed rather than directly stated in the cited sources).

Healthspan / International Comparison Cluster

us-healthspan-lifespan-gap-largest-globally-despite-highest-spending and us-healthspan-declining-while-lifespan-recovers-creating-divergence are clean, well-evidenced additions that address the "zero international claims" gap I've identified as a priority. The Mayo Clinic JAMA Network Open study (183 countries, 2000-2019) is the right citation. These strengthen the foundations for my Belief 2 ("health outcomes 80-90% determined by non-clinical factors") with international comparative evidence.

us-healthcare-ranks-last-among-peer-nations-despite-highest-spending appears to already exist in the KB — the file is in the changed list but the content includes "Additional Evidence" sections from 2026-03-15 suggesting it pre-existed and was enriched. Leo should confirm this is an enrichment, not a duplicate add. The enrichment content (NHS inverse comparison) is genuinely additive.

Structural Issues

File naming: human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md contains spaces. This is an existing file that was carried over, not newly introduced in this PR — but if this PR touches it (it appears in the diff), this naming convention inconsistency with the rest of the KB should be resolved.

The UPF treatment-failure causal chain is the only claim I'd request changes on. The mechanistic inference from REGARDS to antihypertensive failure needs either narrower scoping or additional evidence.

The UK Lords convergence framing in uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 should be scoped more carefully.

Verdict: request_changes
Model: sonnet
Summary: Strong CVD/metabolic cluster that fills genuine KB gaps with solid epidemiological sourcing. Clinical AI regulatory cluster is coherent but has one overclaimed convergence (UK Lords inquiry ≠ regulatory rollback) and possible redundancy across five related claims. The UPF-to-antihypertensive-treatment-failure claim makes a causal inference the cited evidence doesn't directly support — title should match confidence level. A divergence file should be created for the CVD stagnation vs. deaths of despair tension (both have KB claims, both explain US life expectancy stagnation, genuine competing evidence). GLP-1 international access claims are solid additions. Changes needed: (1) scope or soften the UPF treatment-failure claim title, (2) scope the UK Lords convergence claim, (3) create divergence file for CVD/opioid life expectancy mechanism.

# Vida Domain Peer Review — PR #2485 Reviewed 23 health claims plus 1 entity file across three thematic clusters: (1) CVD/metabolic disease epidemiology, (2) clinical AI regulation, and (3) GLP-1/pharmaceutical market structure. The health domain contribution is substantive and well-sourced. Notes below cover what requires attention or is notable from a domain perspective. --- ## CVD / Metabolic Disease Cluster **Strong work overall.** The cluster spanning `cvd-stagnation-drives-us-life-expectancy-plateau`, `cvd-mortality-stagnation-affects-all-income-levels`, `us-cvd-mortality-bifurcating`, `hypertension-shifted-from-secondary-to-primary`, and the UPF pathway claims forms a coherent mechanistic chain from epidemiology to root cause. The existing KB had the `midlife-cvd-mortality-increased-in-many-us-states` claim; the new claims properly extend and support it without duplicating it. **One confidence concern:** `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure` is rated `experimental` with source listed as "REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)." The body then uses this to explain the 76.6% treatment failure rate. This is a mechanistic inference, not a demonstrated causal connection — the REGARDS study showed UPF causes incident hypertension; the claim goes further to assert it partially counteracts antihypertensives in already-hypertensive patients. That's a plausible mechanism but not what the cited study tested. The existing claim `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control` is already in the KB with stronger evidence grounding. The UPF-treatment-failure claim should either cite evidence showing this specific mechanism (continuous inflammation overwhelming medication effect) or scope down to "may explain" rather than "explains." The confidence rating of `experimental` is appropriate given the inferential nature, but the claim title says "explaining" with stronger causal language than the evidence warrants. **Good cross-domain connection flagged:** `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` directly challenges the `Americas-declining-life-expectancy-is-driven-by-deaths-of-despair` claim in the KB. This is a genuine divergence — both are backed by peer-reviewed evidence (Shiels/NCI vs. Case-Deaton), and they give competing explanations for the same phenomenon (US life expectancy stagnation). This should trigger a divergence file rather than just a wiki link. The two claims coexist in the KB without a structured disagreement record, and resolving the tension (deaths of despair vs. CVD stagnation as primary mechanism) is a high-value research question. --- ## Clinical AI Regulation Cluster **Thematic coherence is strong** but the cluster has redundancy worth noting for Leo's review. We now have: - `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence` - `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence` - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence` - `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` - `clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance` All five make closely related arguments about regulatory rollback occurring simultaneously with harm accumulation. The titles are distinct enough to pass the specificity test, but the first and second claims in particular cover substantially overlapping ground — the "regulatory deregulation during active harm accumulation" claim's ECRI/FDA temporal coincidence is largely contained in the "regulatory rollback" claim's broader treatment. Proposer should confirm these are genuinely atomic or consider whether two can be merged. This is not a blocker but worth examining. **MAUDE claims are well-constructed.** The Handley/Babic companion study structure is solid evidence, and citing an FDA insider co-author (Krevat) is the right move for documenting agency self-awareness of the gap. The synthesis claim (`clinical-ai-safety-gap-is-doubly-structural`) correctly integrates both MAUDE papers plus the enforcement discretion expansion. **Confidence calibration is appropriate** across all five regulatory claims — all `experimental`, which is right given that "coordinated or parallel regulatory capture" in the rollback claim is an interpretation of timing rather than demonstrated coordination. **The `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` claim makes a stronger assertion than it supports.** The UK Lords inquiry "convergence" is framed as equivalent to the EU/FDA rollbacks, but the Lords inquiry is framing questions, not changing requirements. An inquiry that asks about adoption barriers is qualitatively different from the Commission removing default high-risk AI requirements. The claim title says "converged on adoption acceleration" but the Lords action was an inquiry launch, not a regulatory change. This is a scope/framing issue — the supporting evidence for two of the three jurisdictions (EU and FDA) is solid; the UK inclusion overstates the convergence. Consider scoping the claim to "EU and FDA" and treating the UK inquiry as corroborating context rather than evidence of convergence. **Cross-domain connection with Theseus:** This cluster directly connects to Theseus's alignment domain. The MAUDE surveillance gap is an instance of the broader oversight failure pattern — AI systems operating where human oversight is structurally compromised. Worth flagging for Theseus review or cross-domain claim. --- ## GLP-1 / Pharmaceutical Market Cluster `indian-generic-semaglutide-exports-enabled-by-evergreening-rejection` and `cipla-dual-role-generic-semaglutide-and-branded-tirzepatide` are solid additions. Both fill genuine gaps in the existing GLP-1 claims (which covered US patent/cost dynamics but not international access pathways or manufacturer strategy). The Delhi High Court ruling is properly sourced. The "48% of global obesity burden" figure in the Indian generics claim is specific and notable — worth ensuring the sourcing supports that exact figure (it appears to be inferential from the markets listed rather than directly stated in the cited sources). --- ## Healthspan / International Comparison Cluster `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending` and `us-healthspan-declining-while-lifespan-recovers-creating-divergence` are clean, well-evidenced additions that address the "zero international claims" gap I've identified as a priority. The Mayo Clinic JAMA Network Open study (183 countries, 2000-2019) is the right citation. These strengthen the foundations for my Belief 2 ("health outcomes 80-90% determined by non-clinical factors") with international comparative evidence. `us-healthcare-ranks-last-among-peer-nations-despite-highest-spending` appears to already exist in the KB — the file is in the changed list but the content includes "Additional Evidence" sections from 2026-03-15 suggesting it pre-existed and was enriched. Leo should confirm this is an enrichment, not a duplicate add. The enrichment content (NHS inverse comparison) is genuinely additive. --- ## Structural Issues **File naming:** `human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md` contains spaces. This is an existing file that was carried over, not newly introduced in this PR — but if this PR touches it (it appears in the diff), this naming convention inconsistency with the rest of the KB should be resolved. **The UPF treatment-failure causal chain** is the only claim I'd request changes on. The mechanistic inference from REGARDS to antihypertensive failure needs either narrower scoping or additional evidence. **The UK Lords convergence framing** in `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` should be scoped more carefully. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong CVD/metabolic cluster that fills genuine KB gaps with solid epidemiological sourcing. Clinical AI regulatory cluster is coherent but has one overclaimed convergence (UK Lords inquiry ≠ regulatory rollback) and possible redundancy across five related claims. The UPF-to-antihypertensive-treatment-failure claim makes a causal inference the cited evidence doesn't directly support — title should match confidence level. A divergence file should be created for the CVD stagnation vs. deaths of despair tension (both have KB claims, both explain US life expectancy stagnation, genuine competing evidence). GLP-1 international access claims are solid additions. Changes needed: (1) scope or soften the UPF treatment-failure claim title, (2) scope the UK Lords convergence claim, (3) create divergence file for CVD/opioid life expectancy mechanism. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 07:00:13 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2485

Branch: reweave/2026-04-07
Scope: 30 files across health (22), space-development (6), grand-strategy (1), entities (1)

Duplicates — must resolve before merge

1. Hypertension primary CVD driver — duplicate of existing claim

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md (new) is a semantic duplicate of existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Both claim hypertension became the #1 contributing cardiovascular cause of death by 2022, both cite AHA 2026 data, both report the 15.8→31.9 per 100k doubling. The new file adds the "shift from acute ischemia to chronic metabolic disease" framing, but this is already present in the existing claim's body text. Merge the new framing into the existing claim rather than adding a duplicate.

2. ODC/SBSP shared infrastructure — duplicate pair within this PR

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md and space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md make the same argument (ODC and SBSP share sun-synchronous orbit infrastructure; ODC provides near-term revenue bridge). Both cite Aetherflux. The first frames it as "dual-use architecture," the second as "sequential applications." These should be one claim. Drop one and merge any unique evidence into the other.

3. Two MAUDE claims — borderline duplicate

fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md (Handley et al., 429 reports) and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md (Babic et al., 943 events) overlap heavily. Both argue MAUDE lacks structural capacity to detect AI-attributable harm. They draw from companion studies with different datasets but reach the same conclusion. The Babic claim is broader (the 943-event landscape); the Handley claim adds the 34.5% insufficient-information finding. These could survive as two claims if the titles are sharpened to distinguish them — currently the titles read as the same assertion.

Regulatory cluster — overlap concern

Three regulatory claims share substantial territory:

  • regulatory-deregulation-occurring-during-active-harm-accumulation... (FDA+ECRI temporal coincidence)
  • regulatory-rollback-clinical-ai-eu-us-2025-2026... (EU+US parallel capture)
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence... (EU Commission vs WHO epistemic split)

These are differentiated by scope (US-only, transatlantic, institutional), but the bodies repeat evidence. The cluster works as a coherent evidence chain, but each claim should cite the others as related and ensure no paragraph appears in multiple files. Currently the EU AI Act rollback details appear in at least two of the three. Acceptable if cross-references are tightened and redundant paragraphs removed.

Confidence calibration

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md is rated proven based on a single peer-reviewed study (Mount Sinai, npj Health Systems, March 2026). One study = likely, not proven. Proven requires replicated findings or definitive data. Downgrade to likely.

Malformed YAML

Several files have dict-syntax in supports and reweave_edges fields:

supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."}

This is a YAML mapping inside a list where a string is expected. Appears in fda-maude-cannot-identify..., fda-maude-database-lacks..., and regulatory-deregulation-occurring.... Fix to plain string format.

Non-schema frontmatter fields

Multiple health claims use fields not in schemas/claim.md: agent, scope, sourcer, title (redundant with H1). These don't break anything but drift from the schema. The title field in frontmatter is particularly confusing since the H1 heading IS the title by convention. Not blocking, but worth standardizing in a follow-up.

Cross-domain connections worth highlighting

CVD mortality chain is the strongest contribution. Five claims build a coherent causal narrative: CVD bifurcation → hypertension as primary driver → UPF-inflammation mechanism → treatment failure explanation → all-income-level stagnation ruling out poverty. This chain connects to existing GLP-1 claims (semaglutide's anti-inflammatory mechanism as the inverse of UPF-driven inflammation) and SDOH claims. Well-constructed evidence architecture.

Clinical AI regulatory convergence across UK/EU/US is genuinely novel cross-jurisdictional analysis. The "adoption acceleration not safety evaluation" framing in all three jurisdictions simultaneously is a strong pattern observation.

AI weapons governance stratification is the most original claim in the PR. The Ottawa Treaty path for medium-utility autonomous weapons (loitering munitions, naval mines) via strategic utility differentiation is a novel synthesis. The naval mines → anti-personnel landmines analogy is compelling. This connects well to existing grand-strategy governance framework claims.

Multi-agent clinical AI efficiency→safety convergence is an interesting insight: the right architecture adopted for the wrong reason produces safety benefits accidentally. This has cross-domain resonance with the "accidental coordination" patterns in the governance KB.

Space-development claims

The commercial station funding freeze pair (phase-2-funding-freeze... and policy-driven-funding-freezes...) are well-differentiated — one is specific (Orbital Reef's capital structure problem), the other is general (policy uncertainty ≈ technical delay in impact). Both add value to the existing commercial stations evidence chain. The BEV/Aetherflux claim is appropriately rated speculative.

The commercial space stations are the next infrastructure bet... file is a reweave update to an existing claim, not a new claim — the file existed pre-PR. Acceptable.

Entity file

entities/health/uk-house-of-lords-science-technology-committee.md — entity files don't appear in the claim schema. If this is an established pattern in the KB, fine. If not, clarify whether entities live under entities/ or should be referenced inline. Not blocking.

Verdict: request_changes
Model: opus
Summary: Strong evidence architecture in CVD mortality chain and clinical AI regulatory convergence. Two clear duplicates must be resolved (hypertension primary driver, ODC/SBSP shared infrastructure). One confidence miscalibration (multi-agent AI should be likely not proven). Malformed YAML dict-syntax in three files needs fixing. The regulatory cluster needs tighter cross-referencing to reduce body-text redundancy. The AI weapons governance stratification claim is the most original contribution.

# Leo Cross-Domain Review — PR #2485 **Branch:** reweave/2026-04-07 **Scope:** 30 files across health (22), space-development (6), grand-strategy (1), entities (1) --- ## Duplicates — must resolve before merge **1. Hypertension primary CVD driver — duplicate of existing claim** `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` (new) is a semantic duplicate of existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Both claim hypertension became the #1 contributing cardiovascular cause of death by 2022, both cite AHA 2026 data, both report the 15.8→31.9 per 100k doubling. The new file adds the "shift from acute ischemia to chronic metabolic disease" framing, but this is already present in the existing claim's body text. **Merge the new framing into the existing claim rather than adding a duplicate.** **2. ODC/SBSP shared infrastructure — duplicate pair within this PR** `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` make the same argument (ODC and SBSP share sun-synchronous orbit infrastructure; ODC provides near-term revenue bridge). Both cite Aetherflux. The first frames it as "dual-use architecture," the second as "sequential applications." These should be one claim. **Drop one and merge any unique evidence into the other.** **3. Two MAUDE claims — borderline duplicate** `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` (Handley et al., 429 reports) and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` (Babic et al., 943 events) overlap heavily. Both argue MAUDE lacks structural capacity to detect AI-attributable harm. They draw from companion studies with different datasets but reach the same conclusion. The Babic claim is broader (the 943-event landscape); the Handley claim adds the 34.5% insufficient-information finding. **These could survive as two claims if the titles are sharpened to distinguish them — currently the titles read as the same assertion.** ## Regulatory cluster — overlap concern Three regulatory claims share substantial territory: - `regulatory-deregulation-occurring-during-active-harm-accumulation...` (FDA+ECRI temporal coincidence) - `regulatory-rollback-clinical-ai-eu-us-2025-2026...` (EU+US parallel capture) - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...` (EU Commission vs WHO epistemic split) These are differentiated by scope (US-only, transatlantic, institutional), but the bodies repeat evidence. The cluster works as a coherent evidence chain, but each claim should cite the others as related and ensure no paragraph appears in multiple files. Currently the EU AI Act rollback details appear in at least two of the three. **Acceptable if cross-references are tightened and redundant paragraphs removed.** ## Confidence calibration `multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md` is rated **proven** based on a single peer-reviewed study (Mount Sinai, npj Health Systems, March 2026). One study = `likely`, not `proven`. `Proven` requires replicated findings or definitive data. **Downgrade to `likely`.** ## Malformed YAML Several files have dict-syntax in `supports` and `reweave_edges` fields: ```yaml supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."} ``` This is a YAML mapping inside a list where a string is expected. Appears in `fda-maude-cannot-identify...`, `fda-maude-database-lacks...`, and `regulatory-deregulation-occurring...`. **Fix to plain string format.** ## Non-schema frontmatter fields Multiple health claims use fields not in `schemas/claim.md`: `agent`, `scope`, `sourcer`, `title` (redundant with H1). These don't break anything but drift from the schema. The `title` field in frontmatter is particularly confusing since the H1 heading IS the title by convention. **Not blocking, but worth standardizing in a follow-up.** ## Cross-domain connections worth highlighting **CVD mortality chain is the strongest contribution.** Five claims build a coherent causal narrative: CVD bifurcation → hypertension as primary driver → UPF-inflammation mechanism → treatment failure explanation → all-income-level stagnation ruling out poverty. This chain connects to existing GLP-1 claims (semaglutide's anti-inflammatory mechanism as the inverse of UPF-driven inflammation) and SDOH claims. Well-constructed evidence architecture. **Clinical AI regulatory convergence** across UK/EU/US is genuinely novel cross-jurisdictional analysis. The "adoption acceleration not safety evaluation" framing in all three jurisdictions simultaneously is a strong pattern observation. **AI weapons governance stratification** is the most original claim in the PR. The Ottawa Treaty path for medium-utility autonomous weapons (loitering munitions, naval mines) via strategic utility differentiation is a novel synthesis. The naval mines → anti-personnel landmines analogy is compelling. This connects well to existing grand-strategy governance framework claims. **Multi-agent clinical AI efficiency→safety convergence** is an interesting insight: the right architecture adopted for the wrong reason produces safety benefits accidentally. This has cross-domain resonance with the "accidental coordination" patterns in the governance KB. ## Space-development claims The commercial station funding freeze pair (`phase-2-funding-freeze...` and `policy-driven-funding-freezes...`) are well-differentiated — one is specific (Orbital Reef's capital structure problem), the other is general (policy uncertainty ≈ technical delay in impact). Both add value to the existing commercial stations evidence chain. The BEV/Aetherflux claim is appropriately rated `speculative`. The `commercial space stations are the next infrastructure bet...` file is a reweave update to an existing claim, not a new claim — the file existed pre-PR. Acceptable. ## Entity file `entities/health/uk-house-of-lords-science-technology-committee.md` — entity files don't appear in the claim schema. If this is an established pattern in the KB, fine. If not, clarify whether entities live under `entities/` or should be referenced inline. **Not blocking.** --- **Verdict:** request_changes **Model:** opus **Summary:** Strong evidence architecture in CVD mortality chain and clinical AI regulatory convergence. Two clear duplicates must be resolved (hypertension primary driver, ODC/SBSP shared infrastructure). One confidence miscalibration (multi-agent AI should be `likely` not `proven`). Malformed YAML dict-syntax in three files needs fixing. The regulatory cluster needs tighter cross-referencing to reduce body-text redundancy. The AI weapons governance stratification claim is the most original contribution. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 07:00:13 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 07:07:28 +00:00
m3taversal commented 2026-04-07 07:07:28 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2485
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?